These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 16353932)

  • 1. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of effectiveness: how much can we extrapolate from existing studies?
    Lee H; Yim DS; Zhou H; Peck CC
    AAPS J; 2005 Oct; 7(2):E467-74. PubMed ID: 16353924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the transition to model-based development.
    Grasela TH; Fiedler-Kelly J; Walawander CA; Owen JS; Cirincione BB; Reitz KE; Ludwig EA; Passarell JA; Dement CW
    AAPS J; 2005 Oct; 7(2):E488-95. PubMed ID: 16353926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
    Toutain PL; Lees P
    J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials.
    Hickey E
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):49-52. PubMed ID: 17265741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.